- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02543541
A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Primary Objective(s): To assess symptoms, adverse events, duration on study, reason for study discontinuation, and quality of life among patients participating in phase I clinical trials who receive structured palliative care, and those who receive standard supportive care. Duration on study will serve as the primary objective for sample size determination.
Secondary Objective(s):
1. To describe the quantity (e.g. hours), type, and cost of palliative care personnel services used by patients and caregivers receiving structured palliative care.
Exploratory:
- To compare adverse event profiles, duration on study, and quality of life between patients who receive structured palliative care and those receiving standard supportive care.
- To compare caregiver burden and quality of life between the study arms.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Comprehensive Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Patient Inclusion Criteria:
- Patients must be enrolled in a Phase 1 clinical trial and be within 2 weeks of starting the experimental therapy or intervention.
- Patients are eligible to enroll on this study with or without the enrollment of their caregiver.
Patient Exclusion Criteria:
- Patients diagnosed with a hematologic malignancy.
Caregiver Inclusion Criteria:
- Any caregiver is considered eligible for this study; The caregiver is the person identified by the patient as the one who provides the most regular physical and/or emotional support.
- Caregivers must be willing to complete surveys at baseline and on monthly basis.
Caregiver Exclusion Criteria:
- Caregivers who are solely professional, paid caregivers
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: Standard Supportive Care
|
Supportive care for the patient and caregiver will be provided by the treating oncologist.
|
Experimental: Structured Supportive Care
|
Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Average total MSAS score
Prazo: Up to 6 months
|
Assessment of patient burden
|
Up to 6 months
|
Average total FACT-G score
Prazo: Up to 6 months
|
Measure patient quality of life
|
Up to 6 months
|
Reason for study discontinuation (Patient reported outcome)
Prazo: Up to 6 months
|
Measure of central tendency for why patients discontinued the phase I study.
Patient reported outcomes for reason for study discontinuation will be qualitatively assessed
|
Up to 6 months
|
Duration on Study
Prazo: Up to 6 months
|
Measure of central tendency of the duration patients were on the phase I study.
Duration on study will serve as the primary objective for sample size determination
|
Up to 6 months
|
Adverse events
Prazo: Up to 6 months
|
Measure of central tendency of adverse events.
AE will be described and further categorized as modifiable (primary symptom experience) and non-modifiable (laboratory abnormalities).
The influence of adverse events on study outcomes particularly duration on study and reason for study discontinuation will be assessed.
An exploratory weighted adverse event score will be calculated using the equation: adverse event score = ∑ (NAE * GAE) where N denotes the adverse event number, G denotes grade, AE denotes adverse event.
These scores will be compared between study arms
|
Up to 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean number of hours of palliative care services
Prazo: Up to 6 months
|
Mean number of hours utilized by patients and caregivers who received structured palliative care.
This analysis will be descriptive, reporting measures of central tendency
|
Up to 6 months
|
Type of palliative care services
Prazo: Up to 6 months
|
Measure of central tendency for the type of palliative care services utilized by patients and caregivers who received structured palliative care.
This analysis will be descriptive, reporting measures of central tendency
|
Up to 6 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Frequency of adverse events of patients receiving structured and usual supportive care
Prazo: Up to 6 months
|
Up to 6 months
|
|
Average days on study
Prazo: Up to 6 months
|
Up to 6 months
|
|
Change in FACT-G score
Prazo: From baseline to last contact, up to 6 months
|
Change in patient symptom burden when compared to baseline between patients who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
Change in MSAS score
Prazo: From baseline to last contact, up to 6 months
|
Change in quality of life when compared to baseline between patients who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
Change in CRA score
Prazo: From baseline to last contact, up to 6 months
|
Change in caregiver burden when compared to baseline between those who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
Change in QOLLTI-F score
Prazo: From baseline to last contact, up to 6 months
|
Change in caregiver quality of life as assessed through change in QOLLTI-F score when compared to baseline between those who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Michelle Treasure, MD, Metrohealth Medical Center and Case Comprehensive Cancer Center
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- CASE5Y15
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
Ensaios clínicos em Standard supportive care
-
Compedica IncProfessional Education and Research InstituteRecrutamentoÚlcera do pé diabéticoEstados Unidos, Canadá
-
Integra LifeSciences CorporationIntegriumRescindidoÚlceras do Pé DiabéticoEstados Unidos, Porto Rico, Canadá, África do Sul
-
ULURU Inc.Navy Advanced Medical Development (NAMD) CommandAtivo, não recrutandoFerimentos e LesõesEstados Unidos
-
Cishan Hospital, Ministry of Health and WelfareConcluídoFragilidade | Sarcopenia | Unidade de Cuidados de Longo PrazoTaiwan
-
Vanderbilt University Medical CenterConcluídoDoença do Refluxo Gastroesofágico (DRGE) | Doença de Refluxo Não Erosiva (NERD)Estados Unidos
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ConcluídoDispepsia Funcional | Doença do Refluxo Gastroesofágico (DRGE) | Esofagite Eosinofílica (EoE)Estados Unidos
-
Saint-Joseph UniversityConcluídoEstabilidade do Implante | Perda óssea peri-implantar | Espessura Vertical dos Tecidos MolesLíbano
-
Icahn School of Medicine at Mount SinaiInternational Biophysics Corporation; SPARK HealthcareRescindidoCovid19 | Doença de obstrução pulmonar crônica | Tosse crônicaEstados Unidos
-
Memorial Sloan Kettering Cancer CenterAmerican Cancer Society, Inc.; Go2 Foundation for Lung CancerRecrutamento
-
ULURU Inc.United States Department of DefenseRecrutamentoÚlcera por Pressão Estágio II | Úlcera por Pressão Estágio III | Úlcera por Pressão, Estágio IVEstados Unidos